The early treatment of Parkinson's disease: Levodopa, dopamine agonists or both

Parkinsonism and Related Disorders

Volumn 7, Issue 1, 2000, Pages 27-33

  Stern, M B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Dopamine agonists; Levopoda; Parkinson's disease

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

ARTICLE; DISEASE COURSE; DYSKINESIA; HUMAN; NEUROPROTECTION; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0033800614     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(00)00045-6     Document Type: Article

References (75)

1. Fahn S. Adverse effects of levodopa. Olanow C.W., Lieberman A.N. The scientific basis for the treatment of Parkinson's disease. 1992;89-112 Parthenon Publishing, Lancashire.
2. Jankovic J. Natural course and limitations of levodopa therapy. Neurology. 43:(Suppl 1):1993;S14-S17.
3. Fabbrini G., Mouradian M., Juncos J.L., et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part 1. Ann Neurol. 24:1988;366-371.
4. Nutt J.G., Holford N.H.G. The response to levodopa in Parkinson's disease:imposing pharmacologic law and order. Ann Neurol. 39:1996;561-573.
5. Gerfen C.R. Dopamine function in the striatum:implications for dopamine receptor agonist treatment of Parkinson's disease. Olanow C.W., Obesso J.A. Beyond the decade of the brain. vol. 2:1997;55-74 Wells Medical Ltd, Kent, UK.
6. Fabbrini G., Mouradian M.M., Juncos J.L., Schlegel J., Mohr E., Chase T.N. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I. Ann Neurol. 24:1988;366-371.
7. de Jong G.J., Meerwaldt J.D., Schmitz P.I. Factors that influence the occurrence of response variations in Parkinson's disease. Ann Neurol. 22:1987;4-7.
8. Simuni T., Stern M.B. Does levodopa accelerate Parkinson's disease. Drugs Aging. 14:(6):1999;399-408.
9. Cross C.E. Oxygen radicals and human disease. Ann Intern Med. 107:1987;526-545.
10. Olanow C.W. An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol. 32:1992;2-9.
11. Olanow C.W. Attempts to obtain neuroprotection in Parkinson's disease. Neurology. 49:(Suppl 1):1997;S26-S33.
12. Perry T.L., Godin D.V., Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency. Neurosci lett. 33:1982;305-310.
13. Sian J., Dexter D.T., Lees A.J., et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol. 36:1994;348-355.
14. Sofic E., Lange K.W., Jellinger K., et al. Reduced and oxidized gluathione in the substantic nigra of patients with Parkinson's disease. Neurosci Lett. 142:1992;128-130.
15. Schapira A.H., Cooper J.M., Dexter D., et al. Mitochondrial complex I deficiency in Parkinson's disease (letter). Lancet. I:(8649):1989;1269.
16. Schapira A.H., Mann V.M., Cooper J.M., et al. Anatomic and disease specificity of NADH CoQ reductase (complex 1) deficiency in Parkinson's disease. J Neurochem. 55:1990;2142-2145.
17. Walkinshaw G., Waters C.M. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA: implications for the treatment of Parkinson's disease. J Clin Invest. 95:1995;2458-2464.
18. Ziv I., Zilkha-Falb R., Offen D., et al. Levodopa induces apoptosis in cultured neuronal cells: a possible accelerator of nigrostriatal degeneration in Parkinson's disease. Mov Disord. 12:1991;17-23.
19. Michel P.P., Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res. 26:1990;426-435.
20. Mytilineou C., Han S.-K., Cohen G. Toxic and protective effects of L-DOPA on mesencepahlic cell cultures. J Neurochem. 61:1993;1470-1478.
21. Pardo B., Mena M.A., Casarejos M.J., et al. Toxic effects of L-dopa on mesencephalic cell cultures: protection with antioxidants. Brain Res. 682:1995;133-143.
22. Ziv I., Offen D., Barzilay A., et al. The protooncogene Bcl-2, a novel cellular protective mechanism against dopamine toxicity: possible implications for Parkinson's disease (abstract). Neurology. 45:(Suppl 4):1995;A279.
23. Han S.K., Mytilineou C., Cohen G. L-dopa up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem. 66:1996;501-510.
24. Mena M.A., Casarejos M.J., Carazo A., et al. Glia conditioned medium protects fetal rat midbrain neurones in culture from L-dopa toxicity. Neuroreport. 7:1996;441-445.
25. Pelton E.W., Kimelberg H.K., Shipherd S.V., et al. Dopamine and norepinephrine uptake and metabolism by astroglial cells in culture. Life Sci. 28:1981;1655-1663.
26. Mena M.A., Davila V., Sulzer D. Neurotrophic effects of L-dopa in postnatal midbrain dopamine/cortical astrocyte cocultures. J Neurochem. 69:1997;1398-1408.
27. Blunt S.B., Jenner P., Marsden C.D. Suppressive effect of L-DOPA on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord. 8:1993;129-133.
28. Murer M.G., Dziwczapolsik G., Menalled L.B., et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery in rats with moderate nigrostriatal lesions. Ann Neurol. 43:1998;561-575.
29. Hefti F., Melamed E., Bhawan J., et al. Long-term administration of L-DOPA does not damage dopaminergic neurons in the mouse. Neurology. 31:1981;1194-1195.
30. Melamed E., Rosenthal J. Can chronic levodopa therapy accelerate degeneration of dopaminergic neurons and progression of Parkinson's disease? Nagtsu T., Fisher A., Yoshida M. Basic, clinical, and therapeutic aspects of Alzheimer's and Parkinson's diseases. 1990;253-256 Plenum Press, New York.
31. Perry T.L., Yong V.W., Ito M., et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-Dopa and carbidopa chronically. J Neurochem. 43:1984;990-993.
32. Quinn N., Parkes D., Janoto J., et al. Preservation of the substantia nigra and locus ceruleus in a patient receiving levodopa plus decarboxylase inhibitor over a four-year period. Mov Disord. 1:1986;65-68.
33. Rajput A.H., Fenton M.E., Dhand A. Is levodopa toxic to non-degenerating substantia nigra cells? Clinical evidence (abstract). Neurology. 46:1996;A371.
34. Rajput A.H., Fenton M.E., Birdi S., et al. Is levodopa toxic to human substantia nigra? Mov Disord. 12:1997;634-638.
35. Kordower J.H., Freeman T.B., Snow B.J., et al. Neuropathological evidence of graft survival and striatal reinnvervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med. 332:1995;1118-1124.
36. Lesser R.P., Fahn S., Snider S.R., et al. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology. 29:1979;1253-1260.
37. Caraceni T., Scigliano G., Mussico M. The occurrence of motor fluctuations in parkinsonian patients treated long-term with levodopa: role of early treatment and disease progression. Neurology. 41:1991;380-384.
38. Mouradian M.M., Heuser I.J.E., Baronti F., et al. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol. 27:1990;18-23.
39. Fahn S. Parkinson's disease, the effect of levodopa and the Elldopa trial. Arch Neurol. 56:1999;529-535.
40. Pearce R.K.B., Banerji T., Jenner P., Marsden C.D. Effects of repeated treatment with L-Dopa, bromocriptine and ropinerole in drug-naive MPTP-treated common marmosets. Br J Pharmacol. 118:1996;37.
41. Rinne U.K. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a five year follow-up. Neurology. 37:1987;826-828.
42. Giovannini P., Scigliano G., Piccolo I., et al. Lisuride in de novo parkinsonian patients a four-year follow-up. Acta Neurol Scand. 77:1988;322-327.
43. Montastruc J.L., Rascol O., Senard J.M., Rascol A. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with PD: a five-year follow-up. J Neurol Neurosurg Psychiatry. 57:1994;1034-1038.
44. Nakanishi T., Mizuno Y., Goto I., et al. A nationwide collaborative study of the long-term effects of bromocriptine in patients with Parkinson's disease. Eur Neurol. 31:(Suppl 1):1991;3-16.
45. Mizuno Y., Kondo T., Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology. 45:(Suppl 3):1995;S13-S21.
46. Przuntek H., Weizel D., Blumner E., et al. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: PRADO study discontinued. Eur J Clin Pharmacol. 43:1992;357-363.
47. Weiner W.J., Factor S.A., Sanchez-Ramos J.R., et al. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology. 43:1993;21-27.
48. Rascol O., Brooks D.J., Korczyn A.D., et al. A five-year study of the incidence of dyskinesia in patients who were treated with ropinerole or levodopa. NEJM. 342:2000;1484-1491.
49. Shaulson I. Pramipexole versus levopa in early Parkinson's disease: the randomized controlled CALM-PD trial. Mov Disord. 15:(Suppl 3):2000;4. (abstracts).
50. Bergamasco B., Benna P., Scarzella L. Long-term bromocriptine treatment of de novo patients with Parkinson's disease: a seven year follow-up. Acta Neurol Scand. 81:1990;383-387.
51. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Br Med J. 307:1993;469-472.
52. Korczyn A.D., Brunt E.R., Larsen J.P., et al. A 3-year randomized trial of ropinerole and bromocriptine in early Parkinson's disease. Neurology. 53:1999;364-370.
53. Shannon K.M., Bennett J.P., Friedman J.H. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mile to moderate Parkinson's disease. Neurology. 49:1997;724-728.
54. Bressman S.B., Shulman L.M., Tanner C.M., et al. Long-term safety and efficacy of pramipexole in early Parkinson's disease. Neurology. 52:(Suppl 2):1999;A261.
55. Barone P., Bravi D., Bermejo-Pareja F., et al. Pergolide monotherapy in the treatment of early PD: a randomized controlled study. Neurology. 53:1999;573-579.
56. Morrish P.K., Rakshi J.S., Bailey D.L., Sawle G.V., Brooks D.J. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with (18F) dopa PET. J Neurol Neurosurg Psychiatry. 64:1998;314-319.
57. Marek K.L., Innis R., Seibyl J. B-CIT/SPECT (New Haven, CT) assessment of determinants of variability in progression of Parkinson's disease. Neurology. 52:(Suppl 2):1999;A91-A92.
58. Carter A.J., Muller R.E. Pramipexole, a dopamine D2 receptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur J Pharmacol. 200:(1):1991;65-72.
59. Ogawa N., Tanaka K., Asanuma M., et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res. 657:1994;207-213.
60. Olanow C.W. Oxidation reactions in Parkinson's disease. Neurology. 40:(Suppl 3):1990;32-37.
61. Felton D.L., Felton S.Y., Fuller R.W., et al. Chronic dietary pergolide preserves nigrostraital neuronal integrity in aged-Fisher-344 rats. Neurobiol Aging. 13:1992;339-351.
62. Clow A., Freestone C., Lewis E., et al. The effect of pergolide and MDL 72974 on rat brain CuZn superoxide dismutase. Neurosci Lett. 164:1993;41-43.
63. Carvey P.M., Pieri S., Ling Z.D. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm. 104:1997;209-228.
64. Sethy1 V.H., Wu H., Oostveen J.A. Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res. 754:1997;181-186.
65. Vincenzi F.F., Hinds T.R. Pramipexole has antioxidant properties and inhibits lipid peroxidation. Proc West Pharmacol Soc. 41:1998;43-46.
66. Cassarino D.S., Fall C.P., Smith T.S., Bennett J.P. Jr. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem. 71:(1):1998;295-301.
67. Zou L., Jankovic J., Rowe D.B., Xie W., Appel S.H., Le W. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci. 64:(15):1999;1275-1285.
68. Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology. 45:(Suppl 3):1995;S6-S12.
69. 3 dopamine receptors in human striatum. Prog Neuropsychopharmacol Biol Psychiatry. 19:1995;1147-1151.
70. 2 dopamine receptors in motor behaviour of patients with Parkinson's disease. Eur Neurol. 3:(Suppl 1):1996;19-24.
71. Goetz C.G., Diederich N.J. Dopaminergic agonists for the treatment of Parkinson's disease. Neurol Clin. 10:1992;527-540.
72. Pezzoli G., Martignoni E., Pacchetti C., et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord. 9:(4):1994;431-436.
73. Bonnet A.M., Serre I., Marconi R., et al. A Combined levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine. Mov Disord. 5:1995;668-671.
74. 4 receptors in functional studies using microphysiometry. Br J Pharmacol. 119:1996;346.
75. 3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol. 312:(1):1996;35-44.